Biocon
Prasad M. is a seasoned professional in the field of quality control, currently serving as Senior Manager Quality Control at Biocon since February 2022, where participation in quality and process improvement initiatives is pivotal. Previously, Prasad held the position of Quality Control Manager at Zydus Group from August 2016 to February 2022, managing a team of 35 and conducting failure investigations. At Mylan, from November 2013 to August 2016, Prasad collaborated with VALIDANT-USA and worked on various quality management software. Early career experiences include a role as Management Staff in Quality Control at Cipla from April 2008 to November 2013, involving analytical method studies and productivity improvement projects with Mckinsey. Prasad holds a Master’s degree in Analytical Chemistry and a Bachelor’s degree in Chemistry, both from Kavayitri Bahinabai Chaudhari North Maharashtra University.
This person is not in any teams
Biocon
21 followers
Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company's brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.